Active Involvement of Patients in Drug Research, Evaluation, and Commercialization: European Perspective

Journal of Ambulatory Care Management

Volumn 27, Issue 2, 2004, Pages 139-145

  Houÿez, François ^a,b  

^a Europ Org for Rare Dis (EURORDIS)   (France)

^b EUROPEAN AIDS TREATMENT GROUP   (Belgium)

Author keywords

Advocacy; Ctivism; Therapeutic expertise

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; LOPINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL RESEARCH; COMMERCIAL PHENOMENA; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; HUMAN; POLICY; REVIEW;

EID: 19244385020     PISSN: 01489917     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004479-200404000-00010     Document Type: Review

References (3)

1. Barbot, J., for CERMES (Centre de Recherche Médecine, Sciences et Société). (in press). Mobilisation for clinical trials and access to new drugs.
2. Dalgalarrondo, S., for National Foundation for Political Sciences, Paris. (2004). A sociological analysis of clinical trials: Strategies of the pharmaceutical industry, clinical research and therapeutic activism. Paris EHESS Press.
3. Epstein, S. (1995). The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials. Science, Technology & Human Values, 20(4), 408-437.